Global EYLEA Drug Market is Segmented By Indication (Wet Age-Related Macular Degeneration (Wet AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Others), By End User (Hospitals, Ophthalmic Clinics, and Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.


Select a License Type that Suits your Business Needs

Excel Databook

US 2,200

Two thousand two hundred dollars

  • Dashboard with market estimates and forecast
  • Raw Data Sheet providing cross-sectional analysis
  • Leading Players Positioning Matrix
  • All segments/taxonomy covered (Statistics)

Single User License

(Full Report)

US$ 4,500

US 3,250

Three thousand two hundred fifty dollars

  • Report accessible by 1 user only
  • Free 20% or 35 hours of customisation
  • Free post-sale service assistance
  • Direct access to lead analyst

Frequently purchased

Multi User License

(Full Report)

US$ 7,000

US 5,250

Five thousand two hundred fifty dollars

  • Report accessible by 7 users
  • Free 30% or 70 hours of customisation
  • Free post-sale service assistance
  • Direct access to lead analysts
  • 25% discount on your next purchase
  • Dedicated account manager
  • Personalized market brief by the lead author, if needed
  • Printable version of the report

Corporate User License

(Full Report)

US$ 10,000

US 6,750

Six thousand seven hundred fifty dollars

  • Report accessible to unlimited users
  • Free 35% or 85 hours of customisation
  • Free post-sale service assistance
  • Direct access to lead analysts
  • 30% discount on your next purchase
  • Dedicated account manager
  • Personalized market brief by the lead author, if needed
  • Printable version of the report